secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001628280-23-028563
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology shifts lead program to first-line RAS-mutated mCRC; Q2 cash burn $7.1M, runway into 2025
--------------------------------------------------------------------------------

- New lead program in first-line RAS-mutated mCRC; interim topline data expected mid-2024; FDA agreed on endpoints for accelerated approval.
- Cash $89.4M as of June 30, 2023; net cash used in operations $7.1M in Q2; runway into 2025.
- Expanded Pfizer relationship: Pfizer Ignite to handle clinical execution of CRDF-004 Phase 2 trial.
- Operating expenses $12.3M for Q2 2023, up from $10.5M in Q2 2022 due to higher headcount and stock-based compensation.
- Upcoming milestones: mPDAC data Q3'23, SCLC data Q3'23, TNBC data Q4'23/Q1'24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/0001628280-23-028563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/crdf-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer